Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Dtsch Dermatol Ges ; 20(2): 141-148, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35119786

RESUMO

Calcinosis cutis is a heterotopic accumulation of calcium salts in the skin. It has been described as a late-onset complication of burn scars in a few cases, in contrast to heterotopic ossification, which may be an early-onset complication of burn injuries. Diagnosis of calcinosis can be confirmed by radiography, ultrasonography, computed tomography, magnetic resonance imaging or histology. Almost all cases of late-onset calcinosis in burn scars present as non-healing ulcers on the lower extremities near contracture bands. It has been hypothesized that this localization is due to the more frequent microtrauma of the lower extremities, and that ulceration is due to the presence of calcium deposits as foreign bodies. In our study, the mean age at the time of burn injury was 12.5 ± 8.27 years, and calcinosis developed after a mean time of 37.5 ± 14.95 years (mean age at onset was 50.5 ± 14.53 years). There was no significant difference between burn scars managed with skin grafting and those where skin grafting was not carried out. The ulcers healed after resection or extraction of the deposits without any recurrence at the same site. In contrast to previously reported cases, we observed two cases of non-ulcerating late-onset calcinosis in burn scars of the upper extremities.


Assuntos
Queimaduras , Calcinose , Neoplasias Cutâneas , Queimaduras/complicações , Queimaduras/patologia , Calcinose/diagnóstico , Calcinose/etiologia , Calcinose/cirurgia , Cicatriz/complicações , Humanos , Neoplasias Cutâneas/patologia , Transplante de Pele
2.
Stem Cells Dev ; 21(1): 152-7, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21288071

RESUMO

Skin samples taken from 6 female patients receiving allogeneic bone marrow transplants (BMT) from male siblings (n=5) or from unrelated human leukocyte antigen (HLA)-matched male donor (n=1) due to hematological malignancies were studied for the presence of donor cells. One nontransplanted male and 1 female control that received female BM were used as further controls of the technique. Skin biopsies were taken from the scalp and the back from each patient 12-16 years after the successful BMT. We have found donor chimerism in all of the 6 patients in both of their biopsies. Using single and double immunostainings in combination with Y chromosome hybridization, we observed that there are cytokeratin-expressing donor-derived cells in the epidermis of all the 6 patients, the numbers being slightly higher in the scalp (0.37%-1.78%) than in the back (0.32%-1.08%) biopsies. The indication for BMT, and the age of the patient did not seem to have any effect on the numbers found. A few of the double-labeled cells also stained for Ki67, a marker of cellular proliferation, suggesting that the engrafted cells were able to further divide in the epidermis. In 2 patients we observed patches of donor keratinocytes within the epidermis, suggesting a clonal origin. We conclude that in agreement with some and in contrast to other published studies, BM-derived circulating cells are able to engraft in the human skin and to further proliferate there and thus contribute to tissue renewal. These data raise the possibility to use BM cells in regenerative medicine to help in extended injuries, large surface burns, or lack of skin due to other reasons.


Assuntos
Transplante de Medula Óssea , Queratinócitos/metabolismo , Pele/patologia , Adulto , Dorso/patologia , Biópsia , Quimera , Cromossomos Humanos Y/metabolismo , Feminino , Neoplasias Hematológicas/terapia , Humanos , Queratinas/metabolismo , Masculino , Pessoa de Meia-Idade , Couro Cabeludo/patologia , Doadores de Tecidos , Transplante Homólogo
3.
Int J Hematol ; 93(4): 545-550, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21360009

RESUMO

A 32-year-old male patient was diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma. Staging FDG PET-CT detected a large right axillary lymph node conglomerate and splenic manifestation. Interim PET-CT following two cycles of ABVD chemotherapy revealed good metabolic response with the exception of a single axillary lymph node. A second "interim" PET-CT after two further cycles showed a similar result. A biopsy of the metabolically active non-palpable lymph node was performed using radioguided occult lesion localization (ROLL) with ultrasound guidance. The lymph node was successfully removed by minimally invasive surgery. Histological evaluation of the lymph node revealed a T cell-rich diffuse large B cell lymphoma. Based on this finding, a more aggressive treatment regimen followed by high dose chemotherapy with autologous stem cell rescue was adopted. To our knowledge, this is the first report of a lymphoma case in which the ROLL method was used in the radioguided biopsy of a chemoresistant lymph node detected by interim FDG PET-CT.


Assuntos
Doença de Hodgkin/diagnóstico por imagem , Linfonodos/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Adulto , Fluordesoxiglucose F18 , Doença de Hodgkin/patologia , Humanos , Linfonodos/patologia , Masculino , Estadiamento de Neoplasias , Compostos Radiofarmacêuticos
4.
Am J Dermatopathol ; 32(7): 708-12, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20644462

RESUMO

A 49 year-old man presented to our clinic. He had a history of lymphomatoid papulosis since childhood. At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed. Chemotherapy resulted in complete remission of the lymphadenopathy. Four years later, systemic relapse was detected which was refractory to therapy. Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells. Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples. The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily. Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.


Assuntos
Linfoma Anaplásico de Células Grandes/patologia , Papulose Linfomatoide/patologia , Segunda Neoplasia Primária/patologia , Neoplasias Cutâneas/patologia , Quinase do Linfoma Anaplásico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Evolução Fatal , Humanos , Linfoma Anaplásico de Células Grandes/tratamento farmacológico , Papulose Linfomatoide/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Segunda Neoplasia Primária/tratamento farmacológico , Proteínas Tirosina Quinases/metabolismo , Receptores Proteína Tirosina Quinases , Neoplasias Cutâneas/tratamento farmacológico
5.
J Neurooncol ; 97(2): 301-4, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19798469

RESUMO

CD4+/CD56+ hematodermic neoplasm, formerly known as blastic NK-cell lymphoma, is an uncommon, aggressive non-Hodgkin's lymphoma with cutaneous, lymph node, and bone marrow involvement at presentation. The disease is characterized by early leukemic phase; however, central nervous system involvement is rarely reported. Herein we describe two cases of CD4+/CD56+ hematodermic neoplasm with meningeal manifestation. Microscopic analysis and flow cytometry of cerebrospinal fluid proved to be diagnostic; however, imaging studies were not informative. These observations call attention to the possibility of central nervous system involvement, which could be more common than expected previously. Authors recommend routine cerebrospinal fluid analysis and prophylactic intrathecal chemotherapy in patients with this highly aggressive disease.


Assuntos
Linfoma Extranodal de Células T-NK/patologia , Linfoma Extranodal de Células T-NK/fisiopatologia , Neoplasias Meníngeas/patologia , Neoplasias Meníngeas/fisiopatologia , Idoso , Antineoplásicos/uso terapêutico , Linfócitos T CD4-Positivos/metabolismo , Linfócitos T CD4-Positivos/patologia , Antígeno CD56/metabolismo , Separação Celular , Evolução Fatal , Feminino , Citometria de Fluxo , Humanos , Imunofenotipagem , Linfoma Extranodal de Células T-NK/terapia , Masculino , Neoplasias Meníngeas/terapia
6.
J Am Acad Dermatol ; 61(5): 885-8, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19632742

RESUMO

Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Pele/irrigação sanguínea , Neoplasias Vasculares/tratamento farmacológico , Antibióticos Antineoplásicos/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Murinos , Antineoplásicos/uso terapêutico , Antineoplásicos Alquilantes/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Feminino , Humanos , Linfoma Difuso de Grandes Células B/patologia , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Indução de Remissão , Rituximab , Gordura Subcutânea/irrigação sanguínea , Neoplasias Vasculares/patologia , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA